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Early Detection and Future Directions*Edward T.H. Yeh, MD,yz Pimprapa Vejpongsa, MDyA dvances in cancer treatment have reducedcancer-related mortality, adding to theranks of cancer survivors (1). Unfortunately,
chemotherapy and radiation often cause acute or
chronic cardiovascular complications, which are the
major causes of noncancer mortality among survivors.
Compared with siblings, cancer survivors are 10 times
more likely to develop coronary disease and 15 times
more likely to develop heart failure (HF) (2). Thus,
screening for cardiovascular complications has
been advocated for patients who have received
anthracycline and/or radiation. In this issue of the
Journal, Armstrong et al. (3) report a cross-sectionalSEE PAGE 2511analysis of cardiac function in long-term childhood
cancer survivors from a single center using transtho-
racic echocardiography to assess myocardial strain
imaging and diastolic function. SJLIFE (St. Jude
Lifetime Cohort Study) analyzed 1,807 childhood
survivors who were diagnosed with cancer
more than 10 years previously and received either
anthracycline or chest radiotherapy or both. Systolic
dysfunction, deﬁned as left ventricular (LV) ejection
fraction (LVEF) < 50%, was detected in only 5.8% of
survivors. Among patients with preserved LV func-
tion, 28% and 8.7% were found to have abnormal
global longitudinal strain (GLS) and diastolic dysfunc-
tion, respectively. These ﬁndings were consistent
with those of previous studies, which demonstrated*Editorials published in the Journal of the American College of Cardiology
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normalities of both systolic and diastolic function
compared with the normal population (4). A recent
meta-analysis suggested that GLS might have prog-
nostic value for the development of cardiotoxicity;
however, this was on the basis of results from 8 studies
with <500 patients, with most of these studies having
only 1 year of follow-up (4). Moreover, the deﬁnition
of cardiotoxicity was ambiguous, and the majority of
patients had LVEFs within the normal range (4). It
should be noted that abnormal GLS is deﬁned as
more than 2 SDs above the mean using sex-speciﬁc,
age-speciﬁc, and vendor-speciﬁc strain values identi-
ﬁed in a normative Japanese study (5). However, the
SJLIFE population is 84% white. The correlation be-
tween the incidence of HF and the cumulative dose
of anthracycline and radiation is well established in
the published research (6). The investigators also
demonstrate a dose-response relationship between
the cumulative anthracycline or radiation dose and
the development of GLS abnormalities. This study
therefore conﬁrms the limitation of current standard
screening with ejection fraction and highlights the
value of strain imaging.
Anthracycline exerts deleterious effects on car-
diomyocytes, endothelial cells, ﬁbroblasts, and car-
diac stem cells. It inhibits topoisomerase II (Top2),
an essential enzyme for unwinding deoxyribonucleic
acid strands during deoxyribonucleic acid replication
or transcription (7). Anthracycline targets Top2b,
the primary Top2 isoform in the heart, triggering
profound changes in the transcriptome that lead
to defective mitochondrial biogenesis and reduced
antioxidative enzymes, manifested as increased
production of reactive oxygen species and car-
diomyocyte death (8). Anthracycline has also been
shown to reduce coronary branching, capillary
density, and the expression of myocardial vascular
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2524endothelial growth factor (9). The number of cardiac
progenitor cells and their ability to differentiate into
endothelial cells, smooth muscle cells, or myocytes
is also diminished (9). Thus, the ability of the heart
to adapt to stress is impaired after exposure to
anthracycline.
A wide range of cardiovascular problems can also
arise from chest radiation therapy (10). Experimental
evidence suggests that endothelial cells are the major
cardiovascular targets of radiation. Mature cardiac
myocytes are terminally differentiated cells and are,
therefore, less sensitive to radiation compared with
endothelial cells. Radiation causes microvascular
and macrovascular damage, the underlying patho-
physiology of radiation-induced heart disease. Path-
ological features of radiation-induced macrovascular
change include adventitial scarring, medial atrophy,
intimal atherosclerosis with necrosis, and ﬁbrocalci-
ﬁcation (10). Disruption of the microvasculature
causes local ischemic injury and an inﬂammatory
response, which triggers the ﬁbroblast proliferation
and an increase in the collagen content of the heart.
These pathological changes may not lead to a reduc-
tion in LVEF but can be detected by a more sensitive
technique, such as GLS.
According to the American College of Cardiology
and American Heart Association guidelines, patients
who received cardiotoxic agents were considered
at risk for developing HF or stage A HF (11). Periodic
LVEF screening has been advocated for this vulner-
able population (12). If LV dysfunction is detected,
HF treatment is often initiated promptly. Even with
aggressive medical management, many cancer sur-
vivors went on to develop stage D HF, which even-
tually required heart transplantation (13). To prevent
further deterioration of LV function, oncocardiolo-
gists have used advanced cardiac imaging and/or
biomarkers to detect LV dysfunction early (4).
Although SJLIFE is the largest study to date usingGLS to detect late cardiotoxicity in cancer survivors,
it provides only a snapshot of the population at
risk, without long-term outcomes.
Even though we can detect subclinical changes of
LV function, the beneﬁt of early detection is still
unknown. A limited number of studies have evalu-
ated the beneﬁt of early intervention in asymp-
tomatic patients with subclinical LV dysfunction,
with contradictory results (14,15). A screening test is
considered cost efﬁcient only if early detection will
lead to intervention that improves outcomes. The
investigators have a unique opportunity to use the
SJLIFE cohort to evaluate whether early intervention
could prevent or slow the progression of subclinical
LV dysfunction (assuming that subclinical LV dys-
function will progress to clinical HF with time). There
is currently no proven treatment that will reverse
cardiac injury that was already incurred after cancer
treatment. It would be more desirable to prevent
cardiovascular damage with primary prevention.
Advances in radiation technology have improved
the ability to deliver safe radiation doses to primary
tumors while sparing normal tissues (16). Primary
prevention for anthracycline-induced cardiotoxicity
is also clinically feasible, albeit rarely practiced (17).
There is no question that a substantial number of
pediatric cancer survivors have evidence for sub-
clinical LV dysfunction. Future studies are required
to examine the progression of subclinical LV dys-
function to clinical cardiomyopathy and to deter-
mine whether early intervention in these patients
will lead to improvements in long-term clinical
outcomes.
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